Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI

Neurology

Volumn 73, Issue 10, 2009, Pages 744-745

  Visser, Pieter Jelle ^a   Knopman, David S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; AMNESIA; COGNITIVE DEFECT; HUMAN; METHODOLOGY; NOTE; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; SCINTISCANNING; SENILE PLAQUE;

ALZHEIMER DISEASE; AMNESIA; CARBON RADIOISOTOPES; COGNITION DISORDERS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENILE PLAQUES;

EID: 70349580516     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b61b5d     Document Type: Editorial

References (10)

1. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 2008;131(Pt 6):1630-1645.
2. 11C-PIB PET study. Neurology 2009;73:754-760.
3. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
4. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
5. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009;132:1355-1365.
6. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-627.
7. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009;30:404-410.
8. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
9. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
10. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725.